Oncology

Studies reveal an AI platform slashes cancer patient hospitalizations by up to 51% and saves millions, heralding a new era of remote oncology care.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

Guerbet appoints independent Chairman Antoine Fady and new directors, signaling a strategic shift as the medical imaging giant celebrates its centenary.

On the sidelines of the World Health Assembly, three startups won major funding for AI tools that predict outbreaks, find cancer, and empower health workers.

Gene Solutions' AI-driven multi-omics liquid biopsy platform makes waves at a major oncology conference, finding a ready market in Taiwan.

Pliant Therapeutics heads to ASCO with data on a novel drug designed to reawaken the immune system's attack on advanced, treatment-resistant tumors.

New data shows Moleculin Biotech's Annamycin avoids heart toxicity, a breakthrough that could transform treatment for leukemia and sarcoma patients.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

Pioneers of IVF technology are launching a clinical skincare program, aiming to merge cellular science with holistic patient support in fertility clinics.

Central Ohio cancer patients gain unprecedented access to advanced therapies and clinical trials as Zangmeister Cancer Center joins OSU's James Cancer Network.

A new data partnership between Ontada and Florida Cancer Specialists aims to transform cancer research by leveraging real-world evidence from community clinics.

With new CEO Andrew Zeringue, Theromics aims to tackle cancer recurrence with its HeatSYNC gel, a novel approach in the booming ablation market.

Following remarkable patient outcomes, Moffitt Cancer Center is scaling its AI-driven virtual care, signaling a major shift in cancer support.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

By hiring a third former FDA oncology leader, Precision for Medicine creates an unparalleled regulatory brain trust to speed up cancer drug approvals.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

With a new CCO and advanced T-Body™ platform, Invenra is shifting from R&D to aggressive commercialization. Can it dominate the multispecific antibody market?

A new collaboration between the digital health giant and a top cancer center aims to deliver expert insights to doctors worldwide, tackling a complex field.

The cancer center's prestigious FACT accreditation for bone marrow transplants brings world-class blood cancer treatment closer to home for patients in Georgia.